Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease: a randomized phase 2 trial - PubMed
7 hours ago
- #Parkinson's disease
- #Fecal microbiota transplantation
- #Gut-brain axis
- Repeated donor fecal microbiota transplantation (dFMT) improves motor and gastrointestinal symptoms in drug-naïve Parkinson's disease (PD) patients.
- The randomized phase 2 trial showed significant improvements in motor symptoms (UPDRS III score) and constipation severity in the dFMT group compared to autologous FMT (aFMT).
- Microbiome changes post-dFMT included reduced Escherichia-Shigella levels and decreased colonic α-synuclein aggregation, supporting a gut-brain axis link in PD.
- The treatment was safe, with only mild and self-limited adverse events reported.
- Biochemical and histological improvements included elevated fecal dopamine metabolites and strengthened gut epithelial barrier integrity.
- The study provides clinical and mechanistic evidence for microbiota modulation as a nonpharmacologic PD therapy.